



DT07 Rec'd PCT/PTO 16 DEC 2004

Docket No. JAB-1704USAPCT

#3

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Anbibaud et al.

Serial No. : 10/509,365

Art Unit:

Filed : September 24, 2004

Examiner:

For : Farnesyl Transferase Inhibiting Tricyclic  
Quinazoline Derivatives Substituted with Carbon-  
Linked Imidazoles or Triazoles

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

December 14, 2004

(Date of Deposit)

Alana Kriegsman

(Name of applicant, assignee, or Registered Representative)

*Alana Kriegsman*  
(Signature)

12-14-04

(Date of Signature)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with \$1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in \$1.17(p).

☐ In accordance with \$1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with \$1.97(e) as set forth below and the fee of \$180.00 as set forth in \$1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

☐ There are no listed references which are not in the English language.

☒ The relevance of those listed references which are not in the English language is as follows: For OERTEL, F. reference, see International Search Report mailed August 5, 2003 for PCT/EP 03/03986, submitted pursuant to MPEP 609 D herewith.

☒ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB-1704USAPCT/AGK. This form is submitted in triplicate.

Respectfully submitted,

Alana Kriegeman

Reg. No. 41,747  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1495  
DATED: December 14, 2004



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/509,365
Filing Date	September 24, 2004
First Named Inventor	Angibaud, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1704 USAPCT

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
		6187786	B1	Venet, M. G., et al	02-13-2001	
		2002/0049327	A1	Venet, M. G., et al	04-25-2002	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
		EP	0371564	A2	Janssen Pharmaceutica N.V.	06-06-1990		
		EP	0371564	B1	Janssen Pharmaceutica N.V.	06-06-1990		
		WO	00/12498	A1	Pfizer Products Inc.	03-09-2000		
		WO	00/12499	A1	Pfizer Products Inc.	03-09-2000		
		WO	97/16443	A1	Janssen Pharmaceutica N.V.	05-09-1997		
		WO	97/21701	A1	Janssen Pharmaceutica N.V.	06-19-1997		
		WO	98/40383	A1	Janssen Pharmaceutica N.V.	09-17-1998		
		WO	98/49157	A1	Janssen Pharmaceutica N.V.	11-05-1998		
		WO	00/39082	A2	Janssen Pharmaceutica N.V.	07-06-2000		
		WO	00/01386	A1	Janssen Pharmaceutica N.V.	01-13-2000		
		WO	98/55124	A1	Janssen Pharmaceutica N.V.	12-10-1998		
		WO	00/01411	A1	Janssen Pharmaceutica N.V.	01-13-2000		
		WO	02/24682	A2	Janssen Pharmaceutica N.V.	03-28-2002		
		WO	02/24683	A1	Janssen Pharmaceutica N.V.	03-28-2002		
		WO	02/24686	A2	Janssen Pharmaceutica N.V.	03-28-2002		
		WO	02/24687	A1	Janssen Pharmaceutica N.V.	03-28-2002		
		WO	01/98302	A1	Janssen Pharmaceutica N.V.	12-27-2001		
		WO	01/53289	A1	Pfizer Products Inc.	07-26-2001		
		WO	00/47574	A1	Pfizer Products Inc.	08-17-2000		

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



Examiner Signature	Date Considered
--------------------	-----------------